Structure-Based Discovery of Novel Non-nucleosidic DNA Alkyltransferase Inhibitors: Virtual Screening and in Vitro and in Vivo Activities
暂无分享,去创建一个
Antonio Morreale | Angel R. Ortiz | Rubén Gil-Redondo | Jerónimo Bravo | Federico M. Ruiz | Carmen Fàbrega | A. Ortiz | J. Bravo | A. Morreale | R. Gil-Redondo | C. Fàbrega | F. M. Ruiz | Antonio Morreale
[1] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[2] L. Erickson,et al. Prolonged Inhibition ofO6-Methylguanine DNA Methyltransferase in Human Tumor Cells by O6-Benzylguanine In Vitro and In Vivo , 1999 .
[3] M. Dolan,et al. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. , 1993, Biochemistry.
[4] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[5] E. Friedberg,et al. DNA Repair and Mutagenesis , 2006 .
[6] M. Dolan,et al. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. , 2006, Cancer treatment reviews.
[7] A. Ortiz,et al. Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets. , 2006, Journal of medicinal chemistry.
[8] Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma , 2005, Clinical Cancer Research.
[9] J. Aqvist,et al. A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.
[10] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[11] A. Pegg,et al. Inactivation of human O(6)-alkylguanine-DNA alkyltransferase by modified oligodeoxyribonucleotides containing O(6)-benzylguanine. , 2001, The Journal of pharmacology and experimental therapeutics.
[12] Y. Mishina,et al. Direct reversal of DNA alkylation damage. , 2006, Chemical reviews.
[13] W. C. Still,et al. Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .
[14] M. Volm,et al. O6‐methylguanine‐DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts , 1998, International journal of cancer.
[15] M. Dolan,et al. Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. , 1994, Cancer research.
[16] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[17] T. McMurry. MGMT inhibitors--The Trinity College-Paterson Institute experience, a chemist's perception. , 2007, DNA repair.
[18] W. Tong,et al. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. , 1982, Cancer research.
[19] A. Ortiz,et al. Evaluation of docking functions for protein-ligand docking. , 2001, Journal of medicinal chemistry.
[20] M. Dolan,et al. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea. , 1995, Biochemical pharmacology.
[21] B. Kaina,et al. Monosaccharide-linked inhibitors of O(6)-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships. , 2001, Journal of medicinal chemistry.
[22] Julien Michel,et al. Protein-ligand binding affinity predictions by implicit solvent simulations: a tool for lead optimization? , 2006, Journal of medicinal chemistry.
[23] A. Pegg,et al. Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. , 2002, Carcinogenesis.
[24] J. Tainer,et al. Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding , 2000, The EMBO journal.
[25] K. Srivenugopal,et al. Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. , 1996, Biochemistry.
[26] J. Tainer,et al. DNA binding and nucleotide flipping by the human DNA repair protein AGT , 2004, Nature Structural &Molecular Biology.
[27] A. Pegg,et al. 2-amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase. , 2004, Journal of medicinal chemistry.
[28] S. Gerson,et al. Acquired resistance to O 6-benzylguanine plus chloroethylnitrosoureas in human breast cancer , 1999, Cancer Chemotherapy and Pharmacology.
[29] M. Fried,et al. Active‐site alkylation destabilizes human O6‐alkylguanine DNA alkyltransferase , 2004, Protein science : a publication of the Protein Society.
[30] Walter Thiel,et al. MINDO/3 Study of the Addition of Singlet Oxygen (1ΔgO2) to 1,3-Butadiene , 1977 .
[31] A. Pegg,et al. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. , 1998, Cancer research.
[32] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[33] M. Ranson,et al. Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors , 2006, Clinical Cancer Research.
[34] P. Kollman,et al. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .
[35] S. Gerson. Clinical relevance of MGMT in the treatment of cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[37] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[38] M. Dolan,et al. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. , 2004, Molecular cancer therapeutics.
[39] J. M. Bogden,et al. A system in mouse liver for the repair of O6-methylguanine lesions in methylated DNA , 1981, Nucleic Acids Res..
[40] P. Houghton,et al. O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[41] James J. P. Stewart,et al. MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..
[42] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[43] Urban Bren,et al. Guanine alkylation by the potent carcinogen aflatoxin B1: quantum chemical calculations. , 2007, Chemical research in toxicology.
[44] Emil Alexov,et al. Rapid grid‐based construction of the molecular surface and the use of induced surface charge to calculate reaction field energies: Applications to the molecular systems and geometric objects , 2002, J. Comput. Chem..
[45] J M Blaney,et al. A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.
[46] G. Margison,et al. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. , 2003, The Lancet. Oncology.
[47] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[48] P. Kollman,et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.
[49] S. Gerson. MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.
[50] A. Pegg,et al. Alteration of arginine-128 to alanine abolishes the ability of human O6-alkylguanine-DNA alkyltransferase to repair methylated DNA but has no effect on its reaction with O6-benzylguanine. , 1995, Biochemistry.
[51] M. Dolan,et al. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[52] R. Schilsky,et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] G. Margison,et al. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. , 2003, Carcinogenesis.
[54] S. Gerson,et al. Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. , 1999, Cancer chemotherapy and pharmacology.
[55] D. Williams,et al. Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[56] Martin J. Stoermer,et al. Current status of virtual screening as analysed by target class. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).
[57] S. Schwartz,et al. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. , 2002, Cancer research.
[58] Lili Liu,et al. Inactivated MGMT by O6-Benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU , 2005, Oncogene.
[59] David Weininger,et al. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..
[60] J. Jiricny,et al. The Effect of O 6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)1-nitrosourea, and Cisplatin , 2003, Journal of Pharmacology and Experimental Therapeutics.
[61] U. Ryde,et al. Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. , 2006, Journal of Medicinal Chemistry.
[62] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[63] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[64] A. Ortiz,et al. A new implicit solvent model for protein–ligand docking , 2007, Proteins.